Crucell Discovers and Validates Human Monoclonal Antibody Product for Protecting against Rabies
22-Nov-2004 -
Dutch biotechnology company
Crucell N.V. announced the discovery and
preclinical validation of an effective monoclonal antibody product for
protection against rabies. The Crucell program has been performed in
close collaboration with two leaders in the rabies antibody field, the
Thomas Jefferson ...
biotechnology
cell lines
Crucell
+2